The role of serum vascular endothelial growth factor and matrix metalloproteinase-9 in predicting response to chemotherapy in patients with advanced nonsmall cell lung cancer

Southern Medical Journal

Volumn 101, Issue 3, 2008, Pages 327-328

  Yazar, Aziz ^a   Soydinc, Hilal ^a   Ertan, Esra ^a   Yasasever, Vildan ^a   Tas, Faruk ^a  

^a ACIBADEM HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; GELATINASE B; VASCULOTROPIN;

BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41849103776     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318164e432     Document Type: Letter

References (5)

1. Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42.
2. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149-153.
3. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum matrix metallo protienase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52:4548-4549.
4. Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006;24:576-580.
5. Lissoni P, Rovelli F, Malugani F, et al. Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 2003;18:152-155.